These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1830 related articles for article (PubMed ID: 15057428)
1. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428 [TBL] [Abstract][Full Text] [Related]
2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Jun; 180(6):331-9. PubMed ID: 15175867 [TBL] [Abstract][Full Text] [Related]
3. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606 [TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976 [TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Tahara H; Lotze MT Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036 [TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity. Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059 [TBL] [Abstract][Full Text] [Related]
9. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877 [TBL] [Abstract][Full Text] [Related]
10. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Becker Y Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514 [TBL] [Abstract][Full Text] [Related]
11. Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD; Hamad GG; Kostuchenko PJ Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208 [TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW; Li D; McQuone SJ; Ralston R Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147 [TBL] [Abstract][Full Text] [Related]
13. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. Habib T; Nelson A; Kaushansky K J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853 [TBL] [Abstract][Full Text] [Related]
14. [Antitumor immunity and cellular cancer therapies]. Catros-Quemener V; Bouet F; Genetet N Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191 [TBL] [Abstract][Full Text] [Related]
15. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation. Miller GM; Andres ML; Gridley DS Int J Oncol; 2003 Dec; 23(6):1585-92. PubMed ID: 14612930 [TBL] [Abstract][Full Text] [Related]
16. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. Crespo FA; Sun X; Cripps JG; Fernandez-Botran R J Leukoc Biol; 2006 Mar; 79(3):586-95. PubMed ID: 16415169 [TBL] [Abstract][Full Text] [Related]
17. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
18. [Molecular bases of cancer immunology]. Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157 [TBL] [Abstract][Full Text] [Related]
19. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Bontkes HJ; Kramer D; Ruizendaal JJ; Meijer CJ; Hooijberg E Clin Immunol; 2008 Jun; 127(3):375-84. PubMed ID: 18358784 [TBL] [Abstract][Full Text] [Related]
20. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]